Stocks and Investing
Stocks and Investing
Thu, February 8, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Patrick Trucchio Reiterated (ARWR) at Strong Buy and Held Target at $90 on, Feb 8th, 2024
Patrick Trucchio of HC Wainwright & Co., Reiterated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy and Held Target at $90 on, Feb 8th, 2024.
Patrick has made no other calls on ARWR in the last 4 months.
There are 4 other peers that have a rating on ARWR. Out of the 4 peers that are also analyzing ARWR, 2 agree with Patrick's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $36 on, Wednesday, February 7th, 2024
- Shawn Egan of "Citigroup" Maintained at Hold with Increased Target to $34 on, Wednesday, February 7th, 2024
These are the ratings of the 2 analyists that currently disagree with Patrick
- Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $50 on, Wednesday, February 7th, 2024
- Jason Gerberry of "B of A Securities" Maintained at Strong Buy with Increased Target to $37 on, Tuesday, January 2nd, 2024
Contributing Sources